Alps Group (ALPS) 주식 개요생명공학 회사인 Alps Group Inc는 첨단 치료법을 위한 연구 개발, 의료 서비스, 웰니스 솔루션을 제공합니다. 자세히 보기ALPS 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성3/6배당0/6강점지난 1년간 수익이 26.7% 증가했습니다.위험 분석지난 1년 동안 주주가 크게 희석되었습니다.의미 있는 수익이 없습니다($4M)의미 있는 시가총액이 없습니다($98M)모든 위험 점검 보기ALPS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.59755.1% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m4m2016201920222025202620282031Revenue US$3.7mEarnings US$689.5kAdvancedSet Fair ValueView all narrativesAlps Group Inc 경쟁사CapForceSymbol: OTCPK:CFORMarket cap: US$111.5mExagenSymbol: NasdaqGM:XGNMarket cap: US$110.7mCue BiopharmaSymbol: NasdaqCM:CUEMarket cap: US$124.4mCibusSymbol: NasdaqCM:CBUSMarket cap: US$108.8m가격 이력 및 성과Alps Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.5952주 최고가US$15.0052주 최저가US$0.56베타-0.171개월 변동-22.36%3개월 변동-41.58%1년 변동n/a3년 변동-94.42%5년 변동n/aIPO 이후 변동-94.01%최근 뉴스 및 업데이트New Risk • 5hNew minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 43x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.7m revenue). Market cap is less than US$100m (US$98.2m market cap).공시 • Jun 25Alps Group Inc Launches Patient-Derived Organoid Program To Advance Personalized Cancer Care In Southeast AsiaAlps Group Inc. announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development. Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8 million in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment market was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR of 10.5%. Alps aims to develop Malaysia’s first clinically validated PDO platform with a defined regulatory pathway that includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment and commercialization. PDO technology involves growing three-dimensional “mini-tumors” from a patient’s own cancer tissue, allowing clinicians and researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment selection, accelerate drug development, and reduce reliance on animal testing. Alps plans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners, with a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial clinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new cancer cases per year. The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at advanced stages.공시 • May 20Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn May 15, 2026, Alps Group Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share. The notification has no immediate effect on the listing or trading of the Company's ordinary shares on Nasdaq, and it does not affect the Company's current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq's continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.공시 • Apr 18Alps Group Inc Appoints Hee H. Lee as Independent Director, Member of Audit and Compensation Committee, Effective April 17, 2026Alps Group Inc. announced the appointment of Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026. The Company's Board will increase from five to six directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of experience in public accounting and advisory services, including his tenure as a Partner at Ernst & Young LLP within its Global Financial Services Organization. During his career, Mr. Lee advised boards of directors and senior management of financial institutions on financial reporting, corporate governance, structured transactions, and capital markets matters. At Ernst & Young, Mr. Lee established and led the Americas Financial Accounting Advisory Services practice within the financial services sector. His experience spans asset management, banking, insurance, private equity, and fintech/digital assets. He has advised on derivatives, securitization, structured financing, initial public offerings, and mergers and acquisitions, and served for more than 20 years as an advisor to the International Swaps and Derivatives Association, contributing to the development and interpretation of industry standards affecting global capital markets. Mr. Lee is a Certified Public Accountant licensed in the State of New York and a member of the American Institute of Certified Public Accountants. He holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration from the University of Louisiana at Lafayette. He has also completed executive education programs in board and leadership development at Harvard University and the Kellogg School of Management.공시 • Jan 08Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer, Effective January 5, 2026Alps Group Inc. announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as risk management, accounting, and treasury responsibilities. Ms. Cheing has over 30 years of experience in finance and accounting, including senior leadership roles in public-listed and private companies across multiple industries. Prior to joining the Company, from 2014 to 2025, Ms. Cheing served as the CFO of a property development company primarily involved in an integrated mixed-use development project in the city center. From 2009 to 2013, she served as Chief Executive Officer of Premier Asia Capital Sdn. Bhd., where she led the company’s investment strategies and managed its investment and joint venture portfolios. From 2003 to 2008, Ms. Cheing headed the corporate affairs department of Equine Capital Berhad, a property development company listed on the Main Market of Bursa Malaysia. In this role, her key responsibilities included financial reporting, corporate finance, corporate governance, risk management, and investor relations. Earlier in her career, from 1995 to 2002, she was with the audit division of Arthur Andersen & Co, where she worked across a range of industries including manufacturing, aviation and logistics, and services. Ms. Cheing holds a Bachelor of Business (Accountancy) from RMIT University, Australia, and a Master of Business Administration from Deakin University, Australia. She is a Chartered Accountant registered with the Malaysian Institute of Accountants and a Fellow of CPA Australia (FCPA).더 많은 업데이트 보기Recent updatesNew Risk • 5hNew minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 43x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.7m revenue). Market cap is less than US$100m (US$98.2m market cap).공시 • Jun 25Alps Group Inc Launches Patient-Derived Organoid Program To Advance Personalized Cancer Care In Southeast AsiaAlps Group Inc. announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development. Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8 million in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment market was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR of 10.5%. Alps aims to develop Malaysia’s first clinically validated PDO platform with a defined regulatory pathway that includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment and commercialization. PDO technology involves growing three-dimensional “mini-tumors” from a patient’s own cancer tissue, allowing clinicians and researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment selection, accelerate drug development, and reduce reliance on animal testing. Alps plans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners, with a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial clinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new cancer cases per year. The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at advanced stages.공시 • May 20Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn May 15, 2026, Alps Group Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share. The notification has no immediate effect on the listing or trading of the Company's ordinary shares on Nasdaq, and it does not affect the Company's current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq's continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.공시 • Apr 18Alps Group Inc Appoints Hee H. Lee as Independent Director, Member of Audit and Compensation Committee, Effective April 17, 2026Alps Group Inc. announced the appointment of Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026. The Company's Board will increase from five to six directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of experience in public accounting and advisory services, including his tenure as a Partner at Ernst & Young LLP within its Global Financial Services Organization. During his career, Mr. Lee advised boards of directors and senior management of financial institutions on financial reporting, corporate governance, structured transactions, and capital markets matters. At Ernst & Young, Mr. Lee established and led the Americas Financial Accounting Advisory Services practice within the financial services sector. His experience spans asset management, banking, insurance, private equity, and fintech/digital assets. He has advised on derivatives, securitization, structured financing, initial public offerings, and mergers and acquisitions, and served for more than 20 years as an advisor to the International Swaps and Derivatives Association, contributing to the development and interpretation of industry standards affecting global capital markets. Mr. Lee is a Certified Public Accountant licensed in the State of New York and a member of the American Institute of Certified Public Accountants. He holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration from the University of Louisiana at Lafayette. He has also completed executive education programs in board and leadership development at Harvard University and the Kellogg School of Management.공시 • Jan 08Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer, Effective January 5, 2026Alps Group Inc. announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as risk management, accounting, and treasury responsibilities. Ms. Cheing has over 30 years of experience in finance and accounting, including senior leadership roles in public-listed and private companies across multiple industries. Prior to joining the Company, from 2014 to 2025, Ms. Cheing served as the CFO of a property development company primarily involved in an integrated mixed-use development project in the city center. From 2009 to 2013, she served as Chief Executive Officer of Premier Asia Capital Sdn. Bhd., where she led the company’s investment strategies and managed its investment and joint venture portfolios. From 2003 to 2008, Ms. Cheing headed the corporate affairs department of Equine Capital Berhad, a property development company listed on the Main Market of Bursa Malaysia. In this role, her key responsibilities included financial reporting, corporate finance, corporate governance, risk management, and investor relations. Earlier in her career, from 1995 to 2002, she was with the audit division of Arthur Andersen & Co, where she worked across a range of industries including manufacturing, aviation and logistics, and services. Ms. Cheing holds a Bachelor of Business (Accountancy) from RMIT University, Australia, and a Master of Business Administration from Deakin University, Australia. She is a Chartered Accountant registered with the Malaysian Institute of Accountants and a Fellow of CPA Australia (FCPA).주주 수익률ALPSUS BiotechsUS 시장7D-9.2%6.1%0.3%1Yn/a40.6%19.9%전체 주주 수익률 보기수익률 대 산업: ALPS의 US Biotechs 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: ALPS의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is ALPS's price volatile compared to industry and market?ALPS volatilityALPS Average Weekly Movement8.3%Biotechs Industry Average Movement10.5%Market Average Movement7.3%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%안정적인 주가: ALPS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: ALPS의 주간 변동성은 지난 1년간 22%에서 8%로 감소했습니다.회사 소개설립직원 수CEO웹사이트n/a93Seng Thamalps-holdings.com생명공학 회사인 알프스 그룹은 첨단 치료법을 위한 연구 개발, 의료 서비스, 웰니스 솔루션을 제공합니다. 말레이시아 쿠알라룸푸르에 본사를 두고 있습니다.더 보기Alps Group Inc 기초 지표 요약Alps Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?ALPS 기초 통계시가총액US$98.18m순이익 (TTM)-US$2.64m매출 (TTM)US$3.74m26.2x주가매출비율(P/S)-37.2x주가수익비율(P/E)ALPS는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표ALPS 손익계산서 (TTM)매출US$3.74m매출원가US$2.83m총이익US$908.62k기타 비용US$3.55m순이익-US$2.64m최근 보고된 실적Sep 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)-0.016총이익률24.29%순이익률-70.59%부채/자본 비율0%ALPS의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 07:20종가2026/06/29 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Alps Group Inc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • 5hNew minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 43x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.7m revenue). Market cap is less than US$100m (US$98.2m market cap).
공시 • Jun 25Alps Group Inc Launches Patient-Derived Organoid Program To Advance Personalized Cancer Care In Southeast AsiaAlps Group Inc. announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development. Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8 million in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment market was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR of 10.5%. Alps aims to develop Malaysia’s first clinically validated PDO platform with a defined regulatory pathway that includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment and commercialization. PDO technology involves growing three-dimensional “mini-tumors” from a patient’s own cancer tissue, allowing clinicians and researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment selection, accelerate drug development, and reduce reliance on animal testing. Alps plans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners, with a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial clinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new cancer cases per year. The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at advanced stages.
공시 • May 20Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn May 15, 2026, Alps Group Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share. The notification has no immediate effect on the listing or trading of the Company's ordinary shares on Nasdaq, and it does not affect the Company's current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq's continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
공시 • Apr 18Alps Group Inc Appoints Hee H. Lee as Independent Director, Member of Audit and Compensation Committee, Effective April 17, 2026Alps Group Inc. announced the appointment of Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026. The Company's Board will increase from five to six directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of experience in public accounting and advisory services, including his tenure as a Partner at Ernst & Young LLP within its Global Financial Services Organization. During his career, Mr. Lee advised boards of directors and senior management of financial institutions on financial reporting, corporate governance, structured transactions, and capital markets matters. At Ernst & Young, Mr. Lee established and led the Americas Financial Accounting Advisory Services practice within the financial services sector. His experience spans asset management, banking, insurance, private equity, and fintech/digital assets. He has advised on derivatives, securitization, structured financing, initial public offerings, and mergers and acquisitions, and served for more than 20 years as an advisor to the International Swaps and Derivatives Association, contributing to the development and interpretation of industry standards affecting global capital markets. Mr. Lee is a Certified Public Accountant licensed in the State of New York and a member of the American Institute of Certified Public Accountants. He holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration from the University of Louisiana at Lafayette. He has also completed executive education programs in board and leadership development at Harvard University and the Kellogg School of Management.
공시 • Jan 08Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer, Effective January 5, 2026Alps Group Inc. announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as risk management, accounting, and treasury responsibilities. Ms. Cheing has over 30 years of experience in finance and accounting, including senior leadership roles in public-listed and private companies across multiple industries. Prior to joining the Company, from 2014 to 2025, Ms. Cheing served as the CFO of a property development company primarily involved in an integrated mixed-use development project in the city center. From 2009 to 2013, she served as Chief Executive Officer of Premier Asia Capital Sdn. Bhd., where she led the company’s investment strategies and managed its investment and joint venture portfolios. From 2003 to 2008, Ms. Cheing headed the corporate affairs department of Equine Capital Berhad, a property development company listed on the Main Market of Bursa Malaysia. In this role, her key responsibilities included financial reporting, corporate finance, corporate governance, risk management, and investor relations. Earlier in her career, from 1995 to 2002, she was with the audit division of Arthur Andersen & Co, where she worked across a range of industries including manufacturing, aviation and logistics, and services. Ms. Cheing holds a Bachelor of Business (Accountancy) from RMIT University, Australia, and a Master of Business Administration from Deakin University, Australia. She is a Chartered Accountant registered with the Malaysian Institute of Accountants and a Fellow of CPA Australia (FCPA).
New Risk • 5hNew minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 43x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.7m revenue). Market cap is less than US$100m (US$98.2m market cap).
공시 • Jun 25Alps Group Inc Launches Patient-Derived Organoid Program To Advance Personalized Cancer Care In Southeast AsiaAlps Group Inc. announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development. Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8 million in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment market was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR of 10.5%. Alps aims to develop Malaysia’s first clinically validated PDO platform with a defined regulatory pathway that includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment and commercialization. PDO technology involves growing three-dimensional “mini-tumors” from a patient’s own cancer tissue, allowing clinicians and researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment selection, accelerate drug development, and reduce reliance on animal testing. Alps plans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners, with a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial clinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new cancer cases per year. The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at advanced stages.
공시 • May 20Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn May 15, 2026, Alps Group Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share. The notification has no immediate effect on the listing or trading of the Company's ordinary shares on Nasdaq, and it does not affect the Company's current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq's continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
공시 • Apr 18Alps Group Inc Appoints Hee H. Lee as Independent Director, Member of Audit and Compensation Committee, Effective April 17, 2026Alps Group Inc. announced the appointment of Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026. The Company's Board will increase from five to six directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of experience in public accounting and advisory services, including his tenure as a Partner at Ernst & Young LLP within its Global Financial Services Organization. During his career, Mr. Lee advised boards of directors and senior management of financial institutions on financial reporting, corporate governance, structured transactions, and capital markets matters. At Ernst & Young, Mr. Lee established and led the Americas Financial Accounting Advisory Services practice within the financial services sector. His experience spans asset management, banking, insurance, private equity, and fintech/digital assets. He has advised on derivatives, securitization, structured financing, initial public offerings, and mergers and acquisitions, and served for more than 20 years as an advisor to the International Swaps and Derivatives Association, contributing to the development and interpretation of industry standards affecting global capital markets. Mr. Lee is a Certified Public Accountant licensed in the State of New York and a member of the American Institute of Certified Public Accountants. He holds a Master of Accountancy and Financial Information Systems from Cleveland State University and a Bachelor of Business Administration from the University of Louisiana at Lafayette. He has also completed executive education programs in board and leadership development at Harvard University and the Kellogg School of Management.
공시 • Jan 08Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer, Effective January 5, 2026Alps Group Inc. announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as risk management, accounting, and treasury responsibilities. Ms. Cheing has over 30 years of experience in finance and accounting, including senior leadership roles in public-listed and private companies across multiple industries. Prior to joining the Company, from 2014 to 2025, Ms. Cheing served as the CFO of a property development company primarily involved in an integrated mixed-use development project in the city center. From 2009 to 2013, she served as Chief Executive Officer of Premier Asia Capital Sdn. Bhd., where she led the company’s investment strategies and managed its investment and joint venture portfolios. From 2003 to 2008, Ms. Cheing headed the corporate affairs department of Equine Capital Berhad, a property development company listed on the Main Market of Bursa Malaysia. In this role, her key responsibilities included financial reporting, corporate finance, corporate governance, risk management, and investor relations. Earlier in her career, from 1995 to 2002, she was with the audit division of Arthur Andersen & Co, where she worked across a range of industries including manufacturing, aviation and logistics, and services. Ms. Cheing holds a Bachelor of Business (Accountancy) from RMIT University, Australia, and a Master of Business Administration from Deakin University, Australia. She is a Chartered Accountant registered with the Malaysian Institute of Accountants and a Fellow of CPA Australia (FCPA).
